Podcasts about expert consensus

Are you unsure which skills you need to thrive as a CME writer (or need for your writers)—or how to prove your value in an increasingly competitive field? Many medical writers stumble into CME with strong writing chops but little clarity about what the role truly demands. At the same time, education providers struggle to find writers who are not just capable—but competent. This episode bridges that gap. Don Harting and Haifa Kassis join us to unpack the results of their groundbreaking Delphi study on CME writing competencies, revealing what hiring managers really want and how you can grow your career strategically. In this episode, you'll learn: The four core competencies every CME writer should master today Which deliverables are in high demand—and which are vanishing How this competency model can support onboarding, training, and upskilling. Press play to learn how to align your writing skills with what the CME industry actually needs—so you can stand out, get hired, and grow with confidence. Resources Kassis, H., & Harting, D. (2024). Medical Writing for Continuing Education in the Health Professions: A Competency Model. Journal of CME, 13(1). https://doi.org/10.1080/28338073.2024.2422709 CME Writers' Toolbox Delphi Panelists WriteCME Pro: Accelerate your freelance CME writing business growth Timestamps 00:00 Introduction to CME Writing Challenges 00:20 Meet the Researchers: Haifa Kassis and Don Harting 01:19 The Competency Model: Key Findings 02:40 Expert Consensus and Methodology 06:16 Surprising Insights and Real-World Challenges 11:15 Practical Applications and Future Directions 24:35 Emerging Competencies and Industry Trends 28:47 Conclusion and Contact Information

Join Bird and Adam for a brand new episode of the Basement Talk Podcast Fantasy Show! Well, you wanted more and here is more! The guys do a PART TWO of player disputes sent in by YOU, the listeners! With Bird's updated 2025 rankings and the Expert Consensus as comparison, who are some of your favorite targets for fantasy football in 2025? Keep it locked in for future episodes of the Basement Talk Podcast Fantasy Show, and do go check out our other podcasts in the Basement Talk Podcast Family of Podcasts!

In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.

In this episode of JACC, Dr. Valentin Fuster explore the 2024 ACC Expert Consensus on arrhythmia monitoring following a stroke, outlining critical insights on stroke types, arrhythmia detection, and anticoagulation strategies. The discussion highlights the complexities of identifying atrial fibrillation post-stroke and the challenges of choosing optimal antithrombotic therapy in diverse stroke cases.

In this podcast, Dr. Valentin Fuster explores the 2024 ACC Expert Consensus on myocarditis, highlighting critical advancements in the understanding, diagnosis, and treatment of this condition. Key takeaways include the introduction of a new four-stage classification, updated diagnostic criteria, and the emphasis on timely referrals, while also addressing the importance of genetic counseling, ongoing patient follow-up, and the need for further research in this evolving field.

In the September 24, 2024, JACC issue, Dr. Valentin Fuster presents the latest expert consensus on heart failure management, updating the 2019 guidelines with ten key changes. Highlights include a strong emphasis on SGLT inhibitors throughout hospitalization and a refined approach to managing heart failure patients, ensuring timely adjustments in therapy and improved patient care strategies.

In the 9th episode of the POCUS Journal podcast, our Editor-In-Chief Dr. Benjamin Galen invited the author Brandon Otto to discuss the expert consensus article entitled “Best Practices for Point of Care Ultrasound: An Interdisciplinary Expert Consensus ”, recently published in POCUS Journal Vol 09 Iss 01, released April 2024. To read the full article visit: https://pocusjournal.com/article/17240/

Brandon summarizes his recent publication describing best practices for performing POCUS. Read the paper open access at POCUS Journal. Find us on Patreon here! Buy your merch here!

In this episode, Dr. Ron George provides a tour de force of our past and present labor analgesia management. We discuss his recent publication, Modern Labor Epidural Analgesia: Implications for Labor Outcomes and Maternal-Fetal Health. https://pubmed.ncbi.nlm.nih.gov/37164496/ The Most Influential Publications in Obstetric Anesthesiology, 1998–2017: Utilizing the Delphi Method for Expert Consensus https://pubmed.ncbi.nlm.nih.gov/32282388/ Effect of low-dose … Read More Read More

CME credits: 0.50 Valid until: 15-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/gprc5d-targeted-bispecifics-in-relapsedrefractory-multiple-myeloma-practical-expert-consensus-on-a-new-target-with-unique-adverse-events/24141/ GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of treatment-emergent adverse events is important to ensure that patients can stay on therapy safely to achieve optimal outcomes. In this educational podcast, myeloma experts weigh in on best-practice management strategies for these toxicities. =

With Stylianos Tzeis (Guest), Cardiology Department and Electrophysiology & Cardiac Pacing Section in Mitera Hospital, Hygeia Group in Athens - Greece and David Duncker (Host), Hannover Heart Rhythm Centre, Hannover - Germany.

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

CME credits: 1.00 Valid until: 12-01-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-consensus-on-how-oxybates-influence-cardiovascular-risk-in-narcolepsy-patients/17925/ This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.This program covers best practices in: Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known Exploring the relationship between cardiovascular disease and Narcolepsy Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle

In this rebroadcasted episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Rachel Grisham, David Gershenson, and Brian Slomovitz to discuss "Low Grade Ovarian Cancer: The Expert Consensus".    Highlights:   A panel of experts convened in October 2022 to discuss recent scientific and clinical progress, resulting in a consensus document that provides recommendations for diagnosis, treatment, and ongoing research to improve patient care of low-grade serous ovarian cancer.  Alterations affecting the MAPK pathway are frequent in low-grade serous ovarian cancer and provide prognostic information  Recent advances in the use of targeted therapy (in particular with novel MEK inhibitor and endocrine therapy regimens) have led to unprecedented response rates in patients with recurrent low-grade serous ovarian cancer 

Dr Jeremy Graber joins us to help answer the question: how often should patients with total knee arthroplasty come to rehabilitation? To answer this and more, we dive into the 2023 JOSPT article, “Expert Consensus for the Use of Outpatient Rehabilitation Visits After Total Knee Arthroplasty: A Delphi Study.” ------------------------------ RESOURCES Dr Graber and his colleagues led a expert consensus process to establish recommendations for how often and for how long you might consider scheduing rehabilitation visits. The group also discussed discharge planning, how to implement telerehabilitation, and monitoring the patient's progress to guide clinical decisions Check out the JOSPT article: https://www.jospt.org/doi/10.2519/jospt.2023.11840 For more on predicting outcomes after total knee replacement: https://www.medrxiv.org/content/10.1101/2023.10.23.23297404v1 (preprint)

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Rachel Grisham, David Gershenson, and Brian Slomovitz to discuss "Low Grade Ovarian Cancer: The Expert Consensus".   Highlights:   A panel of experts convened in October 2022 to discuss recent scientific and clinical progress, resulting in a consensus document that provides recommendations for diagnosis, treatment, and ongoing research to improve patient care of low-grade serous ovarian cancer.  Alterations affecting the MAPK pathway are frequent in low-grade serous ovarian cancer and provide prognostic information.  Recent advances in the use of targeted therapy (in particular with novel MEK inhibitor and endocrine therapy regimens) have led to unprecedented response rates in patients with recurrent low-grade serous ovarian cancer.

In this episode, host Dr. Sabeen Dhand interviews interventional cardiologist Dr. Eric Secemsky about the role of intravascular ultrasound in lower extremity interventions, and how he published a consensus document to standardize its use across specialties and provide a framework for new users. --- CHECK OUT OUR SPONSORS Philips Image Guided Therapy Devices Academy https://resource.philipseliiteacademy.com Philips SymphonySuite https://www.philips.com/symphonysuite --- SHOW NOTES Dr. Secemsky practices at BIDMC in Boston. His passions are pulmonary embolism intervention and intravascular ultrasound (IVUS) for peripheral vascular disease. He began using IVUS for coronary interventions, and then began incorporating it in arterial and venous peripheral interventions. The goal is to make procedures durable in the endovascular world, and IVUS is key for that. In the coronaries, there is a standardized way that all cardiologists use IVUS for. First, they cross the lesion with the wire, then use IVUS to measure lesion length and vessel diameter for stent sizing. They also evaluate plaque composition, which informs whether to use a plaque modifying device before stenting. They then balloon, stent, and use IVUS again to evaluate stent position and check for dissections. Dr. Secemsky measures an arterial lumen by identifying the 3 layers of the vessel wall, and finding the black stripe behind the intima, which corresponds to the elastic membrane. Dr. Secemsky tells us about a consensus article he published in the Journal of the American College of Cardiology. He collaborated with some colleagues to form a 12 person steering committee composed of interventional cardiology, interventional radiology, vascular surgery and vascular medicine specialists. The goal was to consolidate information from all these specialties to provide a single standardized document. This document can be used for those wanting to incorporate IVUS into their practice, but don't know where to begin. They established levels of evidence regarding where IVUS is most appropriate. They found that tibial arterial intervention has the highest support for use of IVUS across specialties. Furthermore, they established that the best practice for IVUS is to use it three times per case, for pre-intervention, middle-run and post-run. Using IVUS is safe, and offers so much information to make case a more efficient. In addition, you cut down on device utilization, contrast use and radiation exposure, while improving patient outcomes by getting better luminal gain and improved durability of your intervention. --- RESOURCES JACC Consensus Article: https://pubmed.ncbi.nlm.nih.gov/35926922/

Editor in Chief Cecelia E. Schmalbach, MD, MSc, hosts a discussion on “Expert Consensus Statement: Management of Dysphagia in Head and Neck Cancer Patients,” which published in the April 2023 issue of Otolaryngology–Head and Neck Surgery. Joining the conversation are authors Maggie A. Kuhn MD, MAS, and M. Boyd Gillespie MD, MSc, and Associate Editor Lee M. Akst, MD. This ECS is the result of a multidisciplinary team comprising experts who reached consensus on recommendations that fill existing clinical practice knowledge gaps. Also discussed are the statements that did not reach consensus, particularly those around the use of reactive and prophylactic feeding tubes. Click here to read the article.

Commentary by Dr. Valentin Fuster

Editor in Chief Cecelia E. Schmalbach, MD, MSc, hosts this podcast on “Expert Consensus Statement: Management of Pediatric Persistent Obstructive Sleep Apnea After Adenotonsillectomy,” which published in the February 2023 issue of Otolaryngology–Head and Neck Surgery. Joining Dr. Schmalbach in conversation are lead author and chair of the expert panel, Stacey L. Ishman, MD, MPH, and coauthor Stephen C. Maturo, MD. This ECS focuses on pediatric patients (between ages 2 and 18) with persistent OSA and on those with recurrent OSA who underwent previous tonsillectomy or adenotonsillectomy, but OSA came back. Rich discussion occurs around how consensus statements concentrate on quality opportunities that exist and areas on which experts agree to put forth best practices. Click here to read the full article.

Please join Guest Host Maryjane Farr, authors Sarah Franklin and Stavros G. Drakos, as well as Associate Editor Hesham Sadek as they discuss the article "Distinct Transcriptomic and Proteomic Profile Specifies Heart Failure Patients With Potential of Myocardial Recovery on Mechanical Unloading and Circulatory Support." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your cohosts. I'm Dr. Carolyn Lam, associate editor from the National Heart Center in Duke National University of Singapore. Dr. Peder Myhre: And I'm Dr. Peder Myhre, social media editor from Akershus University Hospital and University of Oslo. Dr. Carolyn Lam: Peder, today's featured paper is very, very important in the heart failure world. It is such a deep dive into the transcriptomic and proteomic profile that specifies heart failure and the potential of myocardial recovery with mechanical unloading and circulatory support. Dr. Peder Myhre: Can't wait for that feature discussion today, Carolyn. Dr. Carolyn Lam: But you have to wait because I insist on telling you about yet another really important paper, of course in my favorite subject, heart failure with preserved ejection fraction or HFpEF. Now you know that exercise intolerance is a defining characteristic of HFpEF and a marked rise in pulmonary capillary wedge pressure during exertion is pethepneumonic for HFpEF and it's thought to be a key cause of the exercise intolerance. Now if that is true, acutely lowering the wedge pressure should improve exercise capacity, right? Well, don't assume this because to test this hypothesis, authors led by corresponding author Dr. Ben Levine from UT Southwestern evaluated peak exercise capacity with and without nitroglycerin, which was used to acutely lower pulmonary capillary wedge pressure during exercise in patients with HFpEF. Dr. Peder Myhre: Oh, that's so cool. What an amazing research question and Carolyn, you're the best to summarize this. Please tell us what did they find? Dr. Carolyn Lam: Well, they studied 30 patients with HFpEF and get this. They underwent two bouts of upright seated cycle exercise dosed with sublingual nitroglycerin or a placebo every 15 minutes in a single blind randomized crossover design. So really well done. Wedge pressure, VO2 and cardiac output were assessed at rest with 20 watts exercise and at peak exercise during both the placebo and nitroglycerin conditions and the principle finding of the study (singing) acutely lowering pulmonary capillary wedge pressure during upright exercise with nitroglycerin in HFpEF did not improve peak exercise performance. So peak VO2 was practically identical with a 1% difference despite a 17% drop in peak wedge pressure. Peak cardiac output and peak peripheral oxygen extraction were unchanged, again, despite the drop in peak wedge pressure suggesting that oxygen delivery and utilization were unaffected. Exercise performance variables including peak wattage, peak ventilation and peak RER were unchanged, suggesting that again, reductions in peak wedge were insufficient to improve exercise tolerance. All these results suggest acute reductions in wedge pressure are insufficient to improve exercise capacity and provide convincing evidence that a high wedge during exercise by itself is an epiphenomenon perhaps rather than a primary limiting factor for exercise performance in patients with HFpEF. Now of course this is incredibly interesting contrary to hypothesis and so please read the paper. The discussion is very rich. Dr. Peder Myhre: Oh wow, Carolyn. That is such a great paper. I can't wait to pick it up and read it from start to finish and now Carolyn, we're going to look into research within cardiovascular disease from COVID-19 and we have learned so much and so quickly about COVID-19 and its effects on the heart and we have really come a long way from the first case reports reported in the beginning of the pandemic and this paper, which comes to us from corresponding author Professor JP Greenwood, really adds important knowledge to this field. The COVID heart study was a prospective longitudinal multi-center observational cohort study of patients hospitalized with COVID-19 and at elevated serum troponin levels across 25 hospitals in the UK and these investigators aim to characterize myocardial injury, its association and sequela in convalescent patients following hospitalization with COVID-19 utilizing appropriately matched contemporary controls. Dr. Carolyn Lam: Ooh, important stuff. So what did they find? Dr. Peder Myhre: So these authors included in total 519 patients comprising 342 patients with COVID-19 and an elevated troponin, 64 patients with COVID-19 and a normal troponin and 113 age and comorbidity matched controls without COVID-19 and the frequency of any heart abnormality defined as left or right ventricular impairment, scar or pericardial disease was two full greater in patients with COVID positive and troponin positive, so 61% compared to the control groups and that is 36% for COVID positive and troponin negative and 31% for COVID negative and comorbidity positive and the myocardial injury pattern was different for these patients with COVID and an elevated troponin more likely than controls to have infarction and micro infarction. But there was no difference in non-ischemic scar and using the late MRI criteria, the prevalence of probable recent myocarditis was almost 7% for those with COVID and elevated troponin compared to only 2% for the controls without COVID-19 and myocardial scar is but not prior COVID-19 infection or troponin was an independent predictor of MACE. So Carolyn, these authors discussed their findings in light of previously reported studies and these authors identified a lower prevalence of probable recent myocarditis than previously described and a higher proportion of myocardial infarction and this newly described pattern of micro infarction following COVID-19 and Carolyn, there is a brilliant editorial really summarizing this by Dr. Stuber and Baggish entitled "Acute Myocardial Injury in the COVID Heart Study Emphasizing Scars While Reassuring Scarce." I really recommend everyone to pick this up and read the editorial as well. Dr. Carolyn Lam: Very clever title. Thank you. For the last original paper in today's issue, it focuses on the crosstalk between sterile metabolism and inflammatory pathways, which have been demonstrated to significantly impact the development of atherosclerosis. Authors today are featuring and focusing on 25 hydroxy cholesterol, which is produced as an oxidation product of cholesterol and belongs to a family of bioactive cholesterol derivatives produced by cells in response to fluctuating cholesterol levels and immune activation. So these authors with co-corresponding authors, Dr. Suárez and Fernández-Hernando from Yale University School of Medicine, they showed beautifully that first, 25 hydroxy cholesterol accumulates in human coronary atherosclerosis. Next, that 25 hydroxy cholesterol produced by macrophages accelerated atherosclerosis progression and promoted plaque instability by promoting the inflammatory response in macrophages and also via paracrine actions on smooth muscle cell migratory responses. Dr. Peder Myhre: Wow, that is so interesting, Carolyn. What are the therapeutic implications of these findings? Dr. Carolyn Lam: Yes, I'm glad you asked because it was summarizing a lot of work in those findings with the very important implications that inhibition of 25 hydroxy cholesterol production might therefore delay atherosclerosis progression and promote plaque stability. So this study actually opens a door to explore the role of 25 hydroxy cholesterol as a target to control inflammation and plaque stability in human atherosclerosis. Dr. Peder Myhre: Oh, that is so important. Thank you so much and there is more in this issue as well, Carolyn. We have another issue of Circulation Global Rounds and this time we're going to France in a paper written by Dr. Danchin and Bouleti. We also have an exchange of letters by Dr. Yang and Dr. Schultze regarding the article, "Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation" and an ECG Challenge by Drs. Manickavasagam, Dar and Jacob entitled "Syncope After Transcatheter Aortic Valve Implantation: Pace or Not." Dr. Carolyn Lam: Interesting. There's a Frontiers paper also by Dr. Dimopoulos on “Cardiovascular Complications of Down Syndrome: Scoping Review and Expert Consensus,” a Research Letter by Dr. Kimenai on the impact of patient selection on performance of an early rule out pathway for myocardial infarction from research to the real world. Nice. Well let's carry on to that feature discussion on heart failure, transcriptomics and proteomic, shall we? Dr. Peder Myhre: Can't wait. Dr. Maryjane Farr: Welcome everybody to Circulation on the Run. We are so pleased to be talking with Dr. Stavros Drakos and Dr. Sarah Franklin from the University of Utah. My name is Maryjane Farr and I am the heart failure section chief at UT Southwestern and Digital Strategies editor for circulation. Myself and Hesham Sadek will be talking with them about their new paper and circulation called "Distinct Transcriptomic and Proteomic Profile Specifies Heart Failure Patients with Potential of Myocardial Recovery Upon Mechanical Unloading and Circulatory Support." Just briefly, Dr. Stavros Drakos is the director of cardiovascular research for the division of cardiology at Utah and co-director of the Heart Failure Mechanical Circulatory Support and Heart Transplant Program. Dr. Sarah Franklin is associate professor of medicine at the University of Utah whose lab has a specific expertise in the applications of proteomics to heart disease. Welcome, Stavros and Sarah. Dr. Sarah Franklin: Thank you. Dr. Stavros Drakos: Thank you. Thank you for having us. Dr. Maryjane Farr: This paper is exciting for clinicians. It's exciting for translational scientists. Hesham, why don't you start digging into this paper and tell us one or then the other of you tell us what this paper is about, what's the background and let's get into the science. Let's go there and then we'll pull back and look at some of the big picture stuff. Hesham. Hesham Sadek: Well, thank you. So I've been fascinated by the field of cardiac recovery for some time now and obviously Stavros is as an expert and one of the leaders of that field and what struck me about this is that we are starting to see some distinct molecular signature of patients that can experience recovery as opposed to patients undergoing the same procedures with the same profile that do not manifest evidence of myocardial recovery and specifically, the study was conducted very rigorously and the signature was very clear in that they saw primarily interest for someone like me who's interested in cardiac regeneration, a signature of cell cycle in the patients that experience recovery as well as ECM signature which could suggest reverse remodeling and also there's some evidence that ECM might impact cardiomyocyte and myocardial regeneration. So my interest in this for selfish reasons is primarily that this supports the hypothesis that perhaps there is a molecular signature of regeneration that occurs in patients that experience myocardial recovery with LVAD. Dr. Maryjane Farr: So Stavros, let's start with you. Give us the reason why to do this study. You mentioned some of the background. It'd be great to sort of talk for a moment about re-stage heart failure and then how it brought you to this study. Dr. Stavros Drakos: Thank you, Jane. So again, thank you for the opportunity to talk about the findings and the implications of this study. I like the way you are asking us to look a little bit at what led to this study and as you mentioned, the re-stage is a multi-center study that was performed in six US sites which showed in a reproducible fashion now given that we had single center studies from all over the world suggesting that, advanced heart failure is not an irreversible process that has to lead to end stage, an irreversible disease and what a re-stage demonstrated was that there is a subset of patients which if you select them based on clinical characteristics that we derived from other studies that were performed previously, you can achieve reverse remodeling, essentially a bad heart looking much better by every clinical, functional, structural characteristic in up to 50% of the selected patients. That's what re-stage showed. So having this finding now in a multicenter study, what made this study very timely was to be able to understand what drives this remarkable response. What are some of the mechanisms, as Hesham said, that we can if uncover take advantage of and expand this paradigm and enhance it and achieve reverse remodeling and recovery of even more patients and even go earlier in the disease process. So that's kind of how I would link the clinical findings that preceded this study with the motivation to perform the study and the implications of these findings for the ongoing translational and basic science research. Hesham Sadek: I'd like to ask a question here. So Stavros, do you think it's too early to sort of redefine the term reverse remodeling in this context to include perhaps some evidence of regeneration? Is there evidence of regeneration in this field or that's too premature to say? Dr. Stavros Drakos: I think the data are directing us towards the direction you just mentioned. I think that we can begin talking about it and planting the seed. We do have other evidence from work that you and others have performed indicating that this indeed is one of the mechanisms that drives this phenomenon and I think that the findings, especially in the cell cycle that we identified add to and contribute even more to that body of work that you and others have done. At this point, I will turn it to Sarah who can talk a little bit more about the findings related to the cell cycle that we identified in our study and I think that these may complete the answer to you, Hesham. Dr. Sarah Franklin: Yeah, I would love to comment. I think it's a really interesting phenomenon and really in these patient samples we were trying to understand molecularly what the difference is between individuals that respond positively to therapy and individuals that receive the same exact therapy and do not respond positively. So these are termed responders and non-responders and in our analysis we combined two platforms where we could molecularly interrogate what's different in these two tissues and try to see what is differentiating these populations. So what's consistent and reproducible different in responders and non-responders on a molecular level and in both the transcriptomic data and the phospho proteomic data, we saw clear patterns with cell cycle regulation and extracellular matrix or focal adhesion molecules and the interesting thing about cell cycle is cardiomyocytes have typically been thought to exit the cell cycle not long after birth and we see some interesting phenomenon either in humans or mice where we can have nuclei that have either multiple sets of chromosomes or multiple nuclei and there's some differences that have been observed in the nucleus with regards to disease, so hypertrophy, heart failure. So the molecules that we've identified, we saw a large difference in proteins involved in cell cycle regulation. Now the interesting thing is not all of those molecules are increasing or decreasing. We see a combination of molecules that are increasing or decreasing. But I think the other thing that's interesting is that these molecules, even though we are seeing changes in expression or changes in phosphorylation, exactly how that contributes to either cell cycle or cell cycle reentry or just nuclear function and transcription of proteins or genes or DNA regions is still what we need to continue to study. So exactly how these changes in proteins or transcripts related to the cell cycle, how they are exactly contributing to the physiological improvements that we're seeing is something that still needs to be investigated but is really important that that is a highlight of this study and as Stavros mentioned of previous work. Dr. Maryjane Farr: Stavros, tell us the design of the study. Dr. Stavros Drakos: Okay. So this study was performed in 93 patients that were prospectively enrolled in the Utah transplant affiliated hospitals here in Salt Lake City between the University of Utah, Intermountain Medical Center and the VA and these people came from all over the mountain west, the surrounding states of Utah and through our VA, through the state, from all over the west and south, from Alaska and Hawaii to Texas and we think it's a very representative population of our country's patient population and then we followed prospectively these people with serial echocardiograms so we can tell who will respond as Sarah said before, which essentially means which hearts are going to get better by echocardiographic criteria functionally and structurally, the dimensions of the heart shrinking and the ejection fraction improving to more than 40% and the dimension shrinking to normal range and then we compare these people, the subset of patients that have responded to the majority of patients actually that they have not responded. As we know these are advanced end stage patients and there is only a subset of those that they will favor respondents. As we said earlier, these subset can increase if you go selectively and pick these patients based on baseline characteristics. So then we analyze the tissue we got from these people when the LVAD went in, which is the core of the apex of the heart and compare that to the tissue we receive when the patients got transplanted and we got the whole heart. So in the meantime, as we just discussed, we phenotyped these people so we knew who were responders and non-responders and then we went back in the lab and tried to marry two basic processes, analyzing the transcriptome and the proteome and by doing that we were able to see some overlapping changes between the transcriptome and the proteome and we felt that by doing this overlapping analysis, we will increase the likelihood that what we are seeing, exponential mechanistic drivers will be the real mechanism and not just associations that you can frequently find when you do studies in humans and that's kind of a rough, brief summary of the design. Sarah, would you add something to that? Dr. Sarah Franklin: No, I think that's a great overview of it. I think what excites me about it is that this was first clinically observed that these patients were recovering and so I think the exciting part is the hypothesis was that there was some molecular underpinnings that could molecularly define these patients that were responding or not responding and so with that hypothesis we then carried out these analyses hoping that we would see a difference and we're very excited. It's very successful in that we found very clear, molecular differences that are reproducible between these patient populations. Dr. Maryjane Farr: So obviously there's lots of implications. Let me start with one very simple clinical one and that is, so based on some of the differences in the signatures and pathways that you saw for the next patient who needs LVAD therapy and you're trying to predict in some way whether they may be a responder or a non-responder, could you look at a biopsy sample and try to make some sort of prediction based on some of your findings so that they can choose a VAD over a transplant? That's a very clinical question and then I guess the second question is would it have to be a left ventricular myocardial sample? So are the differences? What do you think about that question? Or it's just too much too, far beyond? This is obviously a mechanistic study. But I'm just asking. Dr. Stavros Drakos: No, that's a great question and I'll start and Sarah can add later. So obviously it will be great if we can have a practical way to predict before the intervention who are the people that they will respond and that's one of the motivations for this study. It was not just to find the mechanism so we can make this phenomenon better and enhance it and find the mechanism, create new therapies. It was also the practical approach that you suggested, Jane, and I think that yes, this adds to the clinical predictors that we have already identified from other studies and yes, we could theoretically take the tissue and do this analysis. Is this the most practical thing we can say to the patient to biopsy the heart, right? It would've been better to be able to identify a biomarker in the plaque and we've done that. We started in other studies, identifying what's going on in the tissue and then going targeted in the blood and that's how we identified two cytokines and a two cytokines model, interferon gamma and TNF alpha being predictive as circulating biome. In this study we identify changes that can also inform future studies of biomarkers in the blood. But if we had a way to easily get the tissue and analyze the genes, yes, we could have done that as a predictor as well. The practical issue is that asking a patient for a biopsy just to predict the response to therapy may be something that most patients and most clinicians will consider way too advanced and complicated, right?that's why more work should and could be done to identify circulating biomarkers or other modalities that can help us interrogate what's going on in the heart related with these findings. But not that we cannot also do what you said. It's just more complicated. I don't know if Sarah would like to add to this. Dr. Sarah Franklin: I'd love to. I think that's a great overview. I think the only thing that I would add is that there are a number of conditions whether in the heart or otherwise in the body that you can use a single biomarker and it can be very predictive of conditions. Heart failure is so complex that often individual biomarkers are not sufficient enough to cover an entire population and all the nuances that can go into heart failure symptoms or syndromes and I think the exciting part about this study is it is one of the largest cohorts of patients that have been examined in this manner, which is exciting, but also that we have a multi-factor panel that is made up of multiple biomarkers that with the number of individuals that we examined is completely predictive of all of these patients. So these biomarkers are consistent and reproducible across all of these patients between responders and non-responders regardless of some of the nuances in the heart failure that they have and so it's very exciting because it's possible that a multifactorial panel could be much more applicable and last the test of time more so than an individual biomarker. I think the one other thing that is exciting like Stavros mentioned is that we did initially identify these in the left ventricle and it will be really exciting to see how far these biomarkers can be used if they can be used in potentially other aspects of the heart or blood, which obviously is less invasive and so that's not something that we've applied this panel to yet, but I think is a really wonderful extension of now saying, can we also identify some of these biomarkers in the blood which would be less invasive even if it's a fraction of them. That would still be wonderful. Dr. Maryjane Farr: I have so many clinical questions. But Hesham, what questions do you have? Hesham Sadek: Yeah, so the elephant in the room here obviously is that the variable is that these patients have an unloaded heart and there is evidence that unloading can reverse some of the changes that occur after birth with increasing ventricular load and initiate cascade of molecular events that may allow myocytes to proliferate. So this begs the question, is there a difference in how these ventricles of patients that recover versus those that do not recover see load? Are we able to measure load appropriately and is there a difference in load between these patients and if so, can this be improved or detection or measuring unloading or the degree of unloading clinically, can this be improved? Dr. Stavros Drakos: No, that's a great question and it provides the opportunity to talk about some of the things we can do on the clinical arena to further enhance this phenomenon. Yes, there are ways that we can use to tailor the mechanical unloading that we can provide in order to enhance this phenomenon. One way, and that's a study that we are proposing, is to use sensors, pressure sensors that can guide the way you function the machines, the devices, right? The way you remove part of the load and these sensors, some of them are clinically approved like cardioments and then without doing invasive procedures you can follow chronically how these patients are being unloaded and how the heart is responding to this unloading. We know that a lot of LVAD patients, despite doing clinically well, we know this from snapshot evaluations in right-heart cath studies, they are not optimally unloaded. They are feeling pressures left and right are not always optimized and so by doing this kind of prospective assessment of the mechanical unloading, you can tailor what you offer and the hypothesis generated is that by doing that you may be able to recover even more people. You can do this as we said, with approved sensors like cardioments or with other sensors that they are under investigation. You can also do more invasive stuff like PV loops. Of course these will require cathing these patients, which is a little bit more complicated. But it will provide more accurate assessment and it will also interrogate how the heart is improving and provide to you in-depth investigation and in-depth insights on also how the recovery process and the reverse remodeling process is being, I would say, digested by the heart and translated to functional response instead of just looking at it with an echocardiogram or the findings of a right-heart cath and these are studies that others have performed and have published and we know that they can give you a real good look into the systolic and diastolic function of the heart and how this is changing and improving down the road. So yes, that's the short answer. We can do that and we can tailor the unloading and potentially that's the hypothesis, maximize the effect that we saw here. Hesham Sadek: So this begs the question, maybe two questions here. One, is there evidence that patients who recover not from this study only but from other studies, is there evidence that patients who recover are more unloaded than patients that do not recover and the second question is: is it time to standardize assessment of mechanical load in patients with LVAD, especially those that will undergo or would be considered for recovery? Dr. Stavros Drakos: Yes. So that's a great opportunity to share with our audience what we know and what we don't know in this field in relation to your question about whether we know what is the optimum degree of unloading and the answer I think is that we need to know and understand more. What do I mean by that? There's this idea that the heart as every other organ after being unloaded and not working for some time may it lazy, may get atrophic and may need some rehab like the skeletal muscle when we put it in the cast and get atrophic and we need to rehab it when we remove the cast. So you can imagine that the LVAD and the unloading that provides, which in many cases may take over a significant part of the function of the heart may need gradual reloading as a second phase after the first phase of unloading and that's something that we've done. We have an ongoing study on this and also others have published that it may be beneficial. Of course, it needs to be validated and investigated further and to discuss about the degree of unloading in the first phase and what is the optimum degree of unloading, I would say even there, there is room for us to understand better what's going on and I think that we can investigate with ongoing studies right now whether full unloading versus partial unloading and measure the pressures using these sensors can translate to better changes functionally and structurally. I think that's something that is very doable and it would be very beneficial. What was the second part of your question, Hesham? Hesham Sadek: I was asking whether it's time to start standardizing some measure of unloading if these patients are planned for recovery? Dr. Stavros Drakos: Yes, and that's what we are doing. In all of these people, we report from the get-go what is their recovery score based on the intermixed ICARS derived score and when we have patients that they have high likelihood of recovery, we monitor them very closely and clinically what we do is just looking at the echo and whenever we do a right heart cath for clinical reasons. But in a prospective research study we could do more than just looking at the echo and occasional right heart cath and using the sensors we just discussed previously, you can tailor the unloading and begin prospectively unloading them in a more I would say well monitored wave. Yes. Hesham Sadek: So this is unloading or device specific parameters. Now are there patient specific parameters with regards to type of heart failure? So we talked initially about whether there's an element of regeneration specifically when it comes to cell cycle. But many patients with non-ischemic cardiomyopathy for example, don't have large scars and don't have lot of myocytes as the underlying cause of cardiomyopathy. Would you foresee that there is different mechanisms, for example, in these patients that don't have myocyte loss, that perhaps maybe it's not cardio myocyte proliferation and not regeneration? Dr. Stavros Drakos: Yes. So I think that the differential responses we get based on the heart failure theology warrant further investigation. Sarah and I have discussed that and actually we are following on our findings with larger number of patients so we can tease out these and I'll let Sarah talk a little bit more about it in a minute. But to answer the clinical part of this question, we don't know yet whether different parts of heart failure should be prescribed different modes of unloading. But the way you described it of course invites the hypothesis that of course different substrates, different injuries of the heart, as you said, it's a completely different failing heart if you have a big scar there versus a patient who has a mode of heart failure, another type of injury and would this be treated better and more effectively in terms of reverse remodeling by applying a different mode of unloading? That's things that we need to investigate further. But Sarah, would you like to comment on the potential on the effect of the different heart failure theologies on some of the findings we saw? Dr. Sarah Franklin: Yeah, definitely. So I think it's a really interesting question and in this analysis we included ischemic and non-ischemic samples in the patient populations and really we're just stratifying them based on responders and non-responders. When we start layering additional levels onto that, then we're effectively kind of reducing the potential numbers. So if we have 25 responders and we start breaking that down into ischemic and non-ischemic to see if there's another layer of biomarkers there, we actually did that we did not include it in this study. It's something that we're working on to add that. But we do reduce the number overall of patients in those two populations. So it would be fine to share that we were seeing stratification between ischemic and non-ischemic. But we did not feel like the numbers might be high enough within the responder and non-responder categories that warrant including that in this manuscript. So it's very intriguing that just responders and non-responders alone stratify as well as they do. They separate based on these biomarkers and it looks like it will also be possible in the future for us to even separate these samples further based on similar or additional biomarkers based on more specific factors in the etiology. So I think that will be another really exciting next step for future research. Hesham Sadek: My final question would be maybe a little bit broader than LVAD population, but definitely informed by this study. The term non-ischemic cardiomyopathy, do you think it's too broad and too vague for us to use in this setting because this encompasses many different types of cardiomyopathy that really are not nuanced enough by this definition. Dr. Stavros Drakos: Well, Jane was smiling while you were asking this question because we all as heart failure clinicians need to accept that it was not a good idea to name all of these different diseases non-ischemic cardiomyopathy when we did it or when this happened many moons ago. As you said, Hesham, and I couldn't agree more, these are completely different diseases. We need to understand them better and I think that the way we treat nowadays, chronic heart failure, many years down the road when people will look back, they will consider it a little bit, I would say, surprising that we were treating all of these the same way. We need more studies like the one we just did, that they will have enough numbers and that's when the issue becomes that you need enough numbers to be able to tell the differences between all of these non-ischemic cardiomyopathy types, theologies and if you go upstream, motivated and inspired by findings like this, we hope that we will be able to identify how to go and do a root cause analysis and treat these diseases, not down, down, downstream the same way, but going upstream, finding what really went wrong and treating them earlier in the molecular or other pathophysiological mechanism pathway that led to the heart failure and so yes, it was a bad idea to do that. But of course sometimes we do things because we don't understand it better, right? As one of our keynote speakers here in the recovery symposium said a few years ago, Jay Khan, the founder of Heart Failure Strata of America, some things look complicated until you understand them. Then when you understand them, they look simple. So here we don't really understand non-ischemic cardiomyopathy and how all these theologies lead there and I think studies like these can help us really inform the field better. But we will need, as Sarah said, more numbers. Dr. Maryjane Farr: So that was a great conversation. I wanted to just raise one last thing and that is what's so interesting about this cohort relative to re-stage heart failure is these were older patients and for re-stage heart failure, I think the average age was 35. So you would imagine there might have been one etiology for cardiomyopathy, uncontrolled hypertension or peripartum. But for cohorts in their fifties, there's probably an accumulation of different insults over many years time and so I thought that was particularly interesting from the point of view of that you were probably dealing with, again, a mixed bag of pressure overload, volume overload, maybe a genetic underpinning, whatever the life trajectory of some of these patients were and then lastly, the decision to try to go to recovery rather than to transplant, which would be the real world experience of why this wet pathway than the other. These are people truly in their fifties where they may have one or two surgeries in their lifetime left and so it's the relevant population that you're studying and so I'll leave it at that. That's a comment rather than a question, I think. But I think for heart failure clinicians, this is why the bench to bedside piece is so relevant to understanding this because it actually does change clinical practice, even if the mechanistic pathways may take still many more years to truly understand. It helps understand what's possible from an accrued clinical decision-making level. Dr. Sarah Franklin: Jane, if I might just comment on that, I actually think that's one of the most exciting parts about this dataset is that, as you mentioned, these patients have complex diseases. They are older. But yet we are still able to see consistent and reproducible differences between the patient populations that respond and don't respond and to me that suggests that at the end of the day there are consistent differences or reproducible or consistent molecular changes in cardiac tissue and in response to stress and I think that that gives us hope that we could potentially not only predict who would respond or not respond, but that as we get better at understanding the differences, that there could be potential therapeutic targets or therapies that would still be beneficial regardless of the complexity of the heart failure. Dr. Maryjane Farr: Okay. So Sarah, Stavros, thank you so much for spending time with Hesham and myself and look forward to EUCORS--I'm allowed to say that. Dr. Stavros Drakos: Of course. Dr. Maryjane Farr: Thanks so much. Bye. Dr. Greg Hundley: This program is copyright of the American Heart Association 2023. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Guest: Andrew Menzies-Gow, PhD Host: Charles Turck, PharmD, BCPS, BCCCP Is now the time to shift the asthma management paradigm to prioritize remission as our goal? Dr. Charles Turck is joined by Professor Andrew Menzies-Gow, Director of the Lung Division and Deputy Medical Director at the Royal Brompton and Harefield Hospitals, London, UK, to discuss remission as a goal for patients with asthma. Together, they review a recently published expert consensus framework for asthma remission and discuss whether targeting remission could lead to better outcomes for patients. At the time of recording, Professor Menzies-Gow provided services to AstraZeneca as an External Expert; Professor Menzies-Gow is now a permanent employee at AstraZeneca. ©2022 Amgen and AstraZeneca. All rights reserved. US-69837 Last Updated 12/22

In this World Shared Practice Forum podcast, Dr. Robert Tasker continues highlighting research trends from his position as Editor-in-Chief of the Pediatric Critical Care Medicine Journal. Dr. Tasker presents notable articles from 2022, shares a look into upcoming topics and themes for 2023, and provides his perspective on how academic journals such as PCCM are evolving to meet the needs of modern readers and clinicians. Following this podcast, listeners will be able to: - List some of the prominently featured and shared articles from Pediatric Critical Care Medicine for the first half of 2022 - Identify topics and areas of active research interest within the field of pediatric critical care medicine - Discuss approaches to increasing engagement with an academic publication, including content curation, online presentation, and uses of alternative formats such as podcasting Articles referenced: •2:17 Nellis ME, Karam O, Valentine SL, et al. Executive Summary of Recommendations and Expert Consensus for Plasma and Platelet Transfusion Practice in Critically Ill Children: From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding (TAXI-CAB). Pediatr Crit Care Med. 2022;23(1):34-51. •2:27 Smith HAB, Besunder JB, Betters KA, et al. 2022 Society of Critical Care Medicine Clinical Practice Guidelines on Prevention and Management of Pain, Agitation, Neuromuscular Blockade, and Delirium in Critically Ill Pediatric Patients With Consideration of the ICU Environment and Early Mobility. Pediatr Crit Care Med. 2022;23(2):e74-e110. •3:16 Dewan M. I Cannot Let It Go. Pediatr Crit Care Med. 2022;23(3):214-215. doi:10.1097/PCC.0000000000002862 •4:16 Mazer MB, Bulut Y, Brodsky NN, et al. Multisystem Inflammatory Syndrome in Children: Host Immunologic Responses. Pediatr Crit Care Med. 2022;23(4):315-320. •4:36 Kozyak BW, Fraga MV, Juliano CE, et al. Real-Time Ultrasound Guidance for Umbilical Venous Cannulation in Neonates With Congenital Heart Disease. Pediatr Crit Care Med. 2022;23(5):e257-e266. •5:34 François T, Sauthier M, Charlier J, et al. Impact of Blood Sampling on Anemia in the PICU: A Prospective Cohort Study. Pediatr Crit Care Med. 2022;23(6):435-443. Publish date: December 22, 2022. Citation: Tasker R, Daniel D, Burns JP. Research Trends in Pediatric Critical Care Medicine: Current and Emerging Areas of Interest. 12/2022. Online Podcast. OPENPediatrics. https://youtu.be/tcn-MQ_jHv4. Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open access and thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu

Commentary by Dr. Valentin Fuster

When can COVID survivors return to play? In this interview, Nicole Martin Bhave, MD, FACC, FASE and Eugene Ho-Joon Chung, MD, discuss the ACC Expert Consensus Decision Pathway on COVID-19: Return to Play.

Post-COVID, cardiovascular symptoms may persist or emerge more than 4 weeks after infection. Identifying people with cardiovascular disease sequelae is an important first step. However, many people have cardiovascular syndromes that are not easily identified on standard cardiac testing. More research is needed to better understand these syndromes. In the meantime, we need to come together as a community to share best practices and maximally support patients so that they can return to their daily lives. In this interview, Erica Sarah Spatz, MD, FACC and Alison L. Bailey, MD, FACC, with Tiffany Y. Hu, MD, discuss ACC Expert Consensus Decision Pathway on COVID-19: Post-acute Sequelae.

Murf is back and joins Dan to discuss the release of the FF Playbook, FFCC, UKFFC, and other competitions currently going on.Then the pair share their rankings on the live stream and compare to Expert Consensus.They go into some detail onTom BradyJoe BurrowTua TagovailoaRyan TannehillJared GoffJalen HurtsChristian McCaffreyDerrick HenryD'Andre SwiftDavid MontgomeryJavonte WilliamsRussell Gage,Jaylen WaddleKen WalkerTreylon BurksAnd more...

Attack of the heart muscle by the immune system (myocarditis) is a rare but serious complication of SARS-CoV-2 infection, and an even more rare complication of COVID-19 mRNA vaccination. In this interview, Larry A. Allen, MD, MHS, FACC and Tyler J. Gluckman, MD, FACC, FAHA, discuss the ACC Expert Consensus Decision Pathway on COVID-19: Myocarditis.

Cardiovascular Sequelae of COVID-19 in Adults includes myocaritis, long-COVID, and returning to play. Guest Ty Gluckman, MD, FACC, FAHA, co-chair of the related 2022 Expert Consensus Decision Pathway, shares clinical practices for ID and treatment of those with post-COVID sequelae, evaluating and managing patients who have--or have had--COVID-19, how CV symptoms may manifest weeks or months post-infection, the differences between PASC-CVD and PASC-CVS, and resources for you and your patients.ACC expert consensus decision pathway:https://www.jacc.org/doi/10.1016/j.jacc.2022.02.003 PCNA Membershiphttps://pcna.net/member-center/ PCNA Event calendarhttps://pcna.net/professional-development/event-calendar/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Commentary by Dr. Valentin Fuster

Management of heart failure (HF) has evolved over the past few years, prompting the American College of Cardiology (ACC) to release a 2021 Update to Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment to provide guidance and recommendations on clinical care of HF patients with a reduced ejection fraction (HFrEF). New therapies for HFrEF have emerged that expand the arsenal for this patient population, particularly angiotensin receptor-neprilysin inhibitors (ARNI) and sodium glucose cotransporter-2 (SGLT2) inhibitors. However, use of guideline directed medical therapy (GDMT) is still suboptimal, and there is a need for pharmacists to assist in improving medication adherence. This podcast episode provides general practitioners an update on new evidence for pharmacotherapy and provides guidance on how to initiate GDMT in patients with HFrEF successfully in both inpatient and outpatient settings.      The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In today's podcast episode, we will discuss Point of Care Ultrasonography (POCUS). We examine key trends in technology, the relationship of POCUS to consultative ultrasonography, growing clinical applications, and challenges with POCUS. Our guest is Dr. Jose Luis Diaz-Gomez. Dr. Diaz- Gomez is the Chief of Transplant, Cardiovascular, and Mechanical Support Critical Care, and Director of Critical Care Echocardiography at Baylor, St. Luke's Medical Center in Houston, Texas. He is a Senior Faculty in Cardiovascular Anesthesia and Critical Care at Baylor College of Medicine. Additional Resources: Point of Care Ultrasonography. By J.L. Diaz-Gomez et al. New England Journal of Medicine 2021: https://bit.ly/3JftVPt Multi-organ point of care ultrasound for COVID-19 (PoCUS4COVID). Expert Consensus: https://bit.ly/3mrXvaF Society of Critical Care Medicine Resources for critical care ultrasound: https://bit.ly/3yZsW1m Point of care ultrasonography Certification – CHEST: https://bit.ly/32bZfyd Books Mentioned in this Episode: The Myth of Artificial Intelligence: Why Computers Can't Think the Way We Do. By Erik Larson: https://amzn.to/3ySWDRm Essentialism: The Disciplined Pursuit of Less. By Greg McKeown: https://amzn.to/3EfVeFT

Matt Freedman (@MattFtheOracle) and Thomas Viola (@TVatWork) go through Matt's Week 10 Fantasy Rankings and compare them to where the Expert Consensus ranks stand. To track all of Matt's picks and bets, go to www.ftnbets.com/nfl/bet-trackerFor the video version of the show, head to: youtube.com/BetsTVThe Freedman Fantasy Football Show with Matthew Freedman is brought to you on BetsTV by the FTN Network. Subscribe to FTN Bets at www.ftnbets.com, and use the promo code FREEDMAN for an extra 20% off!

Naomi Lawrence, MD, Dermatologic Surgery Editorial Board member, interviews Nathaniel Jellinek, MD on the Expert Consensus on Nail Procedures and Selection of CPT Codes.

Drs Tucker and Verma discuss Evaluation and Management of Glenohumeral Instability with Associated Bone Loss: An Expert Consensus Statement Using the Modified Delphi Technique

Listen to the Q&A between Prof. Michelle Chew and author Dr Christian Puelacher on his article “Expert consensus on peri-operative myocardial injury screening in noncardiac surgery” and discover further insights.

Host: Matthew J. Sorrentino, MD, FACC, FASH Guest: Sandeep Das, MD, MPH Dr. Sandeep R. Das, Professor of Medicine in the Cardiology Division at the University of Texas Southwestern Medical Center in Dallas, sits down with Dr. Matthew Sorrentino to discuss therapies from the 2020 ACC Expert Consensus Decision Pathways on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes.

Host: Matthew J. Sorrentino, MD, FACC, FASH Guest: Sandeep Das, MD, MPH Dr. Sandeep R. Das, Professor of Medicine in the Cardiology Division at the University of Texas Southwestern Medical Center in Dallas joins Dr. Matthew Sorrentino to discuss implementing the 2020 ACC Expert Consensus Decision Pathways on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes in academic and community settings.

Guest: Ty J. Gluckman, MD, FACC Dr. Ty Gluckman, Medical Director at the Center for Cardiovascular Analytics, Research, and Data Science at Providence St. Joseph Health in Portland, Oregon, gives us a brief overview of his key takeaways from the 2020 ACC Expert Consensus Decision Pathway.

In this week's episode, we talk to Dr. Neuenschwander about the panel discussion on treating Hyperkalemia in the ED.

Guest: Joshua Stolker, MD The 2020 American College of Cardiology Expert Consensus Decision Pathway provides a change in mindset for the cardiology field when it comes to treating patients with type 2 diabetes with established cardiovascular disease. Here to walk us through these updated recommendations is Dr. Joshua Stolker, an interventional cardiologist at Mercy Clinic Heart and Vascular in Saint Louis, Missouri. To view the 2020 American College of Cardiology Expert Consensus Decision Pathway click here. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2021 Novo Nordisk All rights reserved. US20DI00430 January 2021

In this episode, JoAnn Lindenfeld, MD, FACC; Vinay Badhwar, MD, FACC; Sammy Elmariah, MD, MPH, FACC; and Rebecca T. Hahn, MD, FACC, discuss the 2020 Expert Consensus Decision Pathway for mitral regurgitation.

The Journal of Rheumatology's Editor-in-Chief Earl Silverman talks about this month's selection of articles that are most relevant to the clinical rheumatologist. This month's selections include: Expert Consensus on a Set of Outcomes to Assess the Effectiveness of Biologic Treatment in Psoriatic Arthritis: The MERECES Study by Juan D. Cañete, Joan M. Nolla, Ruben Queiro, Miguel J. Rodríguez, Miguel Ruiz and Luis Lizán for the MERECES Working Gro DOI: https://doi.org/10.3899/jrheum.191056 Using Process Improvement and Systems Redesign to Improve Rheumatology Care Quality in a Safety Net Clinic by Alfredo Aguirre, Laura Trupin, Mary Margaretten, Sarah Goglin, Jung Hee Noh and Jinoos Yazdany DOI: https://doi.org/10.3899/jrheum.190472 Analysis of Anti-RNA Polymerase III Antibody-positive Systemic Sclerosis and Altered GPATCH2L and CTNND2 Expression in Scleroderma Renal Crisis by Edward P. Stern, Sandra G. Guerra, Harry Chinque, Vanessa Acquaah, David González-Serna, Markella Ponticos, Javier Martin, Voon H. Ong, Korsa Khan, Svetlana I. Nihtyanova, Mark Harber, Aine Burns, Maureen D. Mayes, Shervin Assassi, Carmen Fonseca and Christopher P. Denton DOI: https://doi.org/10.3899/jrheum.190945 Rituximab and Cyclophosphamide in Antisynthetase Syndrome–related Interstitial Lung Disease: An Observational Retrospective Study by Vincent Langlois, André Gillibert, Yurdagül Uzunhan, Marie-Laure Chabi, Eric Hachulla, Océane Landon-Cardinal, Kuberaka Mariampillai, Nicolas Champtiaux, Hilario Nunes, Olivier Benveniste and Baptiste Hervier DOI: https://doi.org/10.3899/jrheum.190505 Role of Neutrophil Extracellular Traps Regarding Patients at Risk of Increased Disease Activity and Cardiovascular Comorbidity in Systemic Lupus Erythematosus by Stanley Moore, Hsin-Hsuan Juo, Christoffer T. Nielsen, Helena Tyden, Anders A. Bengtsson and Christian Lood DOI: https://doi.org/10.3899/jrheum.190875 To read the full articles visit www.jrheum.org Music by David Hilowitz

In this episode, Christopher Granger is joined by endocrinologist Jennifer Green to discuss the main features from the recently published 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and how to apply the key points from this document in your practice. Visit the CVRiD: Applying Emerging Science to Practice Hub to listen to the other episodes in the series and to access other educational content.

HammerCast Network partner and co-host, David Stidham, takes a shot at a mock draft zero RB strategy.  Great breakdown of players and this strategy!  Where does your guy go!  Dave vs. Expert Consensus!

In medicine, consensus statements abound. They’re issued by government agencies and professional societies as the official word on the science and practice of medicine. But what role does expert consensus serve? To summarize the evidence? To deliberate over decision-making? Or to command change? In an era of evidence-based medicine, is expert consensus going extinct? Or is it perhaps more important now than ever? Philosophers studying the social context of medical knowledge may have some answers. Today’s consultation is with philosopher Miriam Solomon, Professor of Philosophy at Temple University.

After some technical difficulties, we finally got our Norwegian Episode where we cover the Norwegian Expert Consensus Rankings. Special thanks to Anders for all his work making this episode happen and for the great music recs!

Today our guys talk with Jeff Ratcliffe from Pro Football Focus about which players he is much higher and lower on than the Expert Consensus Rankings. Should fantasy owners expect David Montgomery (11:29) to produce better numbers than Jordan Howard did with Chicago last year, does the fantasy community undervalue Alshon Jeffery (27:03), and how concerned should you be about Julian Edelman's (36:39) age? The show ends in a discussion on which rookies we're watching and who we're staying away from (48:09). Is Darrell Henderson (49:51) Todd Gurley's handcuff and how high are we willing to grab Kyler Murray (59:04)? Sponsors: DRAFT - Join the $3.5 million dollar best ball championship on DRAFT! All new players get a FREE entry into a best ball draft upon making their first deposit. Just search DRAFT in the app store or go to DRAFT.com and play for free with promo code FANTASYPROS. NFL Game Pass - Only with NFL Game Pass can you get every out-of-market preseason game LIVE. Kick off the 2019 season with a 7-day free trial of NFL Game Pass. Sign up now at nfl.com/fantasypros Bombas - They make the most comfortable socks in the history of feet. Visit bombas.com/fantasypros and get 20% off your first purchase.

The guys explain which players they largely differ on compared to the Expert Consensus Rankings (ECR) at each position and then engage in a fun, new segment called Fantasy Fill in the Blank (49:15). Is Jared Goff (3:19) QB1 or QB2 material, does Joe Mixon (17:46) have a capped ceiling, and can David Moore (37:59) lead the Seahawks in targets? Toward the end of the show, we take a stab at naming a couple players who could be on the highest percentage of fantasy playoff rosters (59:26). Sponsors: Pristine Auction - Get the best deals in sports memorabilia including signed helmets and custom jerseys with guaranteed authenticity. Enter registration code "FantasyPros" when you sign up to receive a free $5 credit. Plus, enter our special giveaway for free for a chance at a George Kittle signed 49ers helmet. Just go to "fantasypros.com/contest" for more information. DRAFT - Join the $3.5 million dollar best ball championship on DRAFT! All new players get a FREE entry into a best ball draft upon making their first deposit. Just search DRAFT in the app store or go to DRAFT.com and play for free with promo code FANTASYPROS.

In this episode of the SkullKing Fantasy Football Podcast, Ryan takes a moment to rant about the lack of civility when it comes to opinions on fantasy football. He then jumps into the headlines for the past week to discuss Jack Doyle still recovering from injury, Josh Jacobs finally signing his contract, Melvin Gordon demanding a new deal or a trade, and a setback in Derrius Guice's recovery. Finally, Ryan takes a look at a few players whose ADP (average draft position) is a bit different from where the Expert Consensus from FantasyPros have that player ranked, and how that difference should affect how you draft.window.PLAYERCARDS_CONFIG={affiliateCode:"1041"}; Do not forget to order your 2019 SkullKing Draft Guide in either PDF form for a one time download or the Web Version that will be updated throughout the offseason. If you want to be able to hear our podcast while on the go, you can subscribe to our podcast on YouTube, Spotify, iTunes, Stitcher, Google Play, Castbox, Overcast and MORE!!! Don’t forget to check us out on Social Media: Twitter: @skullkingfb Instagram: skullkingfootball Facebook: fb.me/skullkingfantasyfootball All stats provided by StatRoute.com, the best place to get your fantasy statistics and research! All Player Profiles provided by FantasyPros.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/skullkingfb/message Support this podcast: https://anchor.fm/skullkingfb/support

Brito and Dale break down 10 players that differ between ADP rankings and Expert Consensus. Players such as McCaffery, Marvin Jones, Alex Collins, and Rex Burkhead were discussed among others. Thanks for listening and thank to auctionofchampions.com for their partnership and awesome giveaways this year!

JJ Zachariason of numberFire is one of the most well-respected fantasy experts in the industry and he's joining our show today to discuss players he's higher and lower on compared to our expert consensus rankings. Before we get started, Tags and JJ are competing in a quick game of name that player. Play along to see if you know who we're talking about based on the clues given (4:11). We're then going position by position by position -- QB (21:35), RB (27:51), WR (37:03), and TE (51:28) -- and getting JJ's reasoning for his rankings. Sponsors: PristineAuction.com - Get the best deals in sports memorabilia including signed helmets and custom jerseys with guaranteed authenticity. Enter our special giveaway for free for a chance at a signed DeAndre Hopkins jersey. Just go to "fantasypros.com/contest" for more information. SimpleContacts.com/fantasypros - Simple Contacts offers every brand of lenses and their prices are unbeatable. Shipping is free, and you can get $30 off your first order! Just go to our special link or enter the code "fantasypros" at checkout.

This podcast discusses the top 10 things you should remember from the ACC Focused Update on Non-Statin Therapies For LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: Expert Consensus Decision Pathway.

The weekend is here and so is Dave Richard from CBS Sports! Listen in as we dive into Dave's rankings and find out why he's higher and lower on certain players compared to our Expert Consensus (3:26). We're also giving our dissenting opinions on the QB position as we go down all the tiers (26:32). Sponsors: PristineAuction.com - Get authentic, affordable collectibles, and start bidding on items now for free. Sign up for a free account and select FantasyPros as the source. RTSports.com/pros - Play full season fantasy football with top payouts complete with various contest formats, live online drafts or auctions, and fully customized private/home leagues with an award-winning commissioner service. FantasyJocks.com - The best place to get your league a championship belt, trophy, or rings. Take your league to the next level with these high quality prizes. Visit FantasyPros.com, the best source for Expert Consensus Rankings - Subscribe to our YouTube channel: bit.ly/fpros-subscribe - Follow us on Twitter: @FantasyPros - Support the podcast and subscribe:podcast.fantasypros.com

We've got a special episode for you today with the one and only Christopher Harris of Harris Football. Listen in as we run through his most recent rankings and get his thoughts on why he's higher and lower on certain players like Brandon Marshall (5:23), Sammy Watkins (14:19), Terrelle Pryor (16:14), and Martellus Bennett (28:37) to name a few. We've also got a bonus segment as we run a dynasty mock draft to wrap up the show (33:10). Sponsors: PristineAuction.com - Get authentic, affordable collectibles, and start bidding on items now for free. Sign up for a free account and select FantasyPros as the source. RTSports.com/pros - Play full season fantasy football with top payouts complete with various contest formats, live online drafts or auctions, and fully customized private/home leagues with an award-winning commissioner service. Visit FantasyPros.com, the best source for Expert Consensus Rankings - Subscribe to our YouTube channel: bit.ly/fpros-subscribe - Follow us on Twitter: @FantasyPros - Support the podcast and subscribe: podcast.fantasypros.com

We're excited to welcome Rotoworld's Evan Silva to the show today after he recently published his top 150 fantasy players. Hear directly from the expert's mouth on why he's got his rankings the way he does as we dig into who he's higher and lower on such as Terrelle Pryor (12:33), Stefon Diggs (18:45), John Brown (22:10), Derrick Henry (39:05), and many others. We're also finding out who he's ending up with the most on his MFL teams (48:34). Visit FantasyPros.com, the best source for Expert Consensus Rankings - Subscribe to our YouTube channel: http://bit.ly/fpros-subscribe - Follow us on Twitter: @FantasyPros - Support the podcast and subscribe: http://podcast.fantasypros.com

Mike Tagliere (@MikeTagliereNFL) of Pro Football Focus joins the show to discuss his rankings versus the Expert Consensus heading into Week 16. Topics include: 2016 MVP picks (1:04); rankings for quarterbacks (8:26), running backs (16:25), wide receivers (29:36), tight ends (36:51), and defenses (42:04).

Chris Harris (@HarrisFootball) from HarrisFootball.com joins the show to discuss his Week 14 rankings compared to the Expert Consensus. Topics include: Jeremy Maclin's return possibly making an impact on Tyreek Hill's production (0:51); Derek Carr (2:28); Jameis Winston (6:37); Tom Brady (11:00); Marcus Mariota (13:23); Devontae Booker (16:30); Todd Gurley (18:25); Theo Riddick (22:39); Devante Adams (25:37); Tyrell Williams (28:04); Randall Cobb (30:50); Sterling Shepard (33:05); Cameron Brate (35:25); Vernon Davis (37:35); Hunter Henry (39:53); and defenses (43:26).

Sean Koerner (@The_Oddsmaker) - this year's most accurate fantasy expert - from Stats.com joins us to preview Week 12 of the NFL season and to compare his rankings to the Expert Consensus. Topics include: the Philadelphia offense (5:34); Sean's rankings for quarterbacks (7:37), running backs (18:33), wide receivers (29:31), tight ends (41:49), and defenses (48:49) compared to our Expert Consensus Rankings (ECR). Sponsor: PlayDraft.com. Play one-week fantasy games with fast snake drafts. Use promo code fantasypros for a 100% deposit bonus!

Mike Tagliere (@MikeTagliereNFL) of ProFootballFocus joins us to discuss his Week 11 rankings and compare them to the Expert Consensus. Topics include: Christine Michael being cut by the Seahawks and what that means for him and the team going forward (1:48); Rob Gronkowski's injury (7:43); Jordan Howard's injury (10:49); Dion Lewis' role going forward (12:53); quarterback rankings (14:53); running back rankings (22:36); wide receiver rankings (34:03); tight end rankings (43:22); and defenses worth streaming (48:42). Sponsor: PlayDraft.com. Play one-week fantasy games with fast snake drafts. Use promo code fantasypros for a 100% deposit bonus!

Matt Harmon (@MattHarmon_BYB) of NFL.com joins us to discuss his rankings versus the Expert Consensus. Topics include rankings for quarterbacks (2:22); running backs (10:06); wide receivers (23:36); tight ends (32:21); and defenses (36:29).

James Koh (@JamesDKoh) of NFL.com and Greg Smith (@gregsauce) of twoqbs.com join us to discuss Week 9 rankings. We begin with James Koh, and topics include; Jamaal Charles' injury (0:44); Percy Harvin signing with the Bills (6:05); Norv Turner stepping down as the Vikings Offensive Coordinator (8:56); our mid-season awards (12:55); players who could carry fantasy teams through the second half (30:15); and tight ends that could serve as some good insurance moving forward (34:25). Greg Smith joins us at (40:28) to discuss his Week 9 rankings in relation to the Expert Consensus. Topics include quarterbacks (41:12); running backs (46:10); wide receivers (50:21); tight ends (54:06); and defenses (58:05).

Today we are joined by Dalton Del Don (@daltondeldon) of Yahoo! Sports to discuss the latest NFL news and Dalton's Week 6 rankings compared to the Expert Consensus. We begin by looking at Justin Forsett signing with the Lions and if he's worth a spot on fantasy rosters (2:01), Colin Kaepernick's value as a starter moving forward (2:48), and how the Jets and their receiving corps will deal with Eric Decker's injury (6:14). Moving on to Dalton's rankings versus the Expert Consensus, we start with quarterbacks (7:42), continue with running backs (17:26), wide receivers (27:13), and finish with team defenses (34:05). We end with some bold predictions for Week 6 (38:04).

Andy Behrens (@andybehrens) of Yahoo! Sports joins us to look ahead to Week 5 matchups and Andy's rankings compared to the Expert Consensus. We begin by trying to unpack the recent news concerning Odell Beckham Jr's motivation (1:48) and then we move on to quarterbacks and examine some signal callers Andy likes better or worse compared to the expert's consensus (5:20). We continue with running backs and discuss the Miami backfield (11:24), Terrence West (13:51) James White (16:41), Zach Zenner (18:40) and Duke Johnson (19:33). We move on to wide receivers (21:09) and look at how Sammy Coates, Tajae Sharpe, Victor Cruz, Terrelle Pryor, Mike Wallace, and Chris Hogan are ranked by Andy compared to the consensus. We then look at tight ends and why Andy likes Kyle Rudolph and Jason Witten in their Week 5 games (33:02). We take a quick look at some intriguing DST plays (36:05) before finishing up with bold predictions for this week's slate of games (38:21).

Jeff Ratcliffe of ProFootballFocus joins host, Bobby Sylvester to discuss big NFL news (1:07), Jeff's week 3 rankings compared to the Expert Consensus (9:40), questions from our listener mailbag (37:39), start/sit (49:22) and top predicted performers of the week (53:03). Player mentions: Adrian Peterson, Jerick McKinnon and Matt Asiata (1:07), Ameer Abdullah and Dwayne Washington (3:20), Donte Moncrief, Phillip Dorsett (5:33), Ezekiel Elliott and Alfred Morris (7:00), Doug Martin (7:25), Jay Cutler (7:30), Josh Gordon (7:45), Ryan Tannehill (10:08), Dak Prescott (12:19), Carson Wentz (12:44), Russell Wilson (13:49), Ben Roethlisberger (15:32), Cam Newton (16:22), Justin Forsett and Kenneth Dixon (18:05), Jeremy Hill (19:24), Shane Vareen and Rashad Jennings (21:09), Thomas Rawls, Christine Michael and C.J. Prosise (22:26), Devante Parker (26:00), Michael Thomas, Willie Snead and Brandin Cooks (28:07), Le'Veon Bell (31:44), Mike Wallace and Breshard Perriman (33:01), Julian Edleman (34:55), Will Fuller and Sterling Shepard (35:55), Le'Veon Bell and Odell Beckham Jr. (37:39), Theo Riddick (42:58), Blial Powell, Kevin White, Derrick Henry (44:12), Tavon Austin, Steve Smith, Darren Sproles , Ryan Matthews (46:43), Derrick Carr and Jameis Winston (49:22), Jamaal Charles, Carlos Hyde, Jay Ajayi (50:22), Corey Coleman (51:43), Matt Ryan and Drew Brees (53:03), Charles Sims, DeAngelo Williams, Melvin Gordon (54:02), Dez Bryant and Marvin Jones (57:05), Delanie Walker and Antonio Gates (55:53)

Matt Lutovsky (@MLutovsky) of The Sporting News joins us to discuss weekly rankings, answer some mailbag and Start/Sit questions, and give bold predictions for Week 2. We begin with the Seahawks backfield and speculate how the Christine Michael/Thomas Rawls dynamic will play out going forward (0:45), which quarterbacks we have ranked higher (2:49) and lower (7:23) than the Expert Consensus, and running backs we like better (12:15) or worse (15:50) than the consensus. Bobby and Matt have a quick discussion about whether to start Sammy Watkins and Travis Benjamin (18:13), before moving on to receivers they are high (21:18) and low (26:18) on for Week 2. On to the listener mailbag where we answer questions about whether you should trade Tom Brady for Blake Bortles (28:30), who between Sammy Watkins and Josh Gordon will play more games this season (29:52), if you should be concerned with Coby Fleener's Week 1 usage (31:54), if you should buy low on Todd Gurly (33:59), who to drop between Charles Simms, Jerick McKinnon and Tevin Coleman (37:08), and what defenses with a good Week 3 matchup are worth picking up sooner rather than later (38:41). We move on to our start/sit segment and pick two players each from a group of four quarterbacks (40:50), running backs (42:02) and wide receivers (43:25) that we'd start this week. We finish by making bold predictions about which quarterback (45:36), running back (49:04), wide receiver (51:04), and tight end (53:01) has a chance to finish with the most fantasy points at their position for Week 2.

Scott Pianowski (@scott_pianowski) of Yahoo Sports joint us to cover news of the week and players he likes better and worse than the Expert Consensus. We begin with Tony Romo's injury and Dak Prescott's value in drafts (1:10), whether you should take Prescott or Robert Griffin III (2:11), if Josh Gordon is worth a reach (3:22), Ezekiel Elliot's off-field concerns and if that will impact his production (4:51), A.J. Green's injury scare (6:04), and if Jimmy Graham is still a viable tight end (7:48). Moving on, we discuss players Scott is higher and lower on compared to the Expert Consensus Rankings. Players include Andrew Luck (8:51), Doug Baldwin (13:05), Ameer Abdullah (17:05), Zach Zenner (18:45), Rashad Jennings (19:22), Dez Bryant (21:24), Kevin White (23:17), Brandin Cooks (25:01) and Vincent Jackson (25:53). We finish by asking Scott for a player outside the top 100 that has a chance to finish in the top 20 at the end of the season (26:53).

Christopher Harris (@HarrisFootball) joins us to talk about the players he likes better and worse than the Expert Consensus. We begin with quarterbacks Tom Brady (3:14) and Kirk Cousins (5:31) before moving on to running backs David Johnson (7:52), Jamaal Charles (10:45), Jonathan Stewart (12:59), Demarco Murray (18:54) and Duke Johnson (20:18). We finish by discussing wide receivers Larry Fitzgerald (22:47), Marvin Jones (26:23), FantasyPros podcast favorite Donte Moncrief (27:15), and Kevin White (27:48).

On today's episode, host Bobby Sylvester (@bobbyfantasypro) is joined by Jamey Eisenberg (@JameyEisenberg) of CBS Sports to discuss a wide range of topics. We begin with a quick discussion of IDP leagues (1:47), Spencer Ware's status as the handcuff for Jamaal Charles (3:36), and Malcom Mitchell's preseason hype (5:08). We move on to the players Jamey likes better and worse than the Expert Consensus. The group includes Tom Brady (7:58), Ben Roethlisberger (10:19), Eddie Lacy (12:06), Thomas Rawls (13:57), Devonta Freeman (17:35), Rashad Jennings (19:17), Matt Forte (21:08), Donte Moncrief (22:42), Sterling Shepard (25:04), Sammie Coates (26:24), and Jordan Matthews (28:41).

We're joined by Jake Ciely of RotoExperts.com to discuss the players Jake is high and low on compared to the Expert Consensus. First, we cover News including Ryan Matthews and his draft status (4:50), the Bills rushing game (6:13), injured pass catchers (7:05), Jimmy Graham's status (8:40) and Jared Cook with the Packers (10:30) before we get into Jake's draft rankings. Players discussed include David Johnson (12:50), Eddie Lacy (16:13), Matt Forte (17:50), Michael Floyd (19:50), Brandon Marshall (22:02), Rob Gronkowski (24:37), Thomas Rawls (27:45), Dion Lewis (31:01), Jeremy Hill and Derek Henry (33:03). Producer JP shares his bearish player (39:15) and we finish with Jake showing off his trivia chops (42:05).

Summary: In this episode our guest is Master Lipidologist, Dr. Peter Howard Jones from Baylor College of Medicine and the National Lipid Association. My guest host is Dr. Paul Williams, Clinician Educator extraordinaire from Philadelphia. We explore everything you’ll ever want to know about cholesterol and lipids. Are statins still king when it comes to cholesterol lowering? Should we be rushing to use PCSK9 inhibitors? Should we throw away older drugs like fibrates? Are nonpharmacologic therapies like niacin and fish oil worthwhile? Join us for this extensive conversation.   Disclosures: Dr. Jones is the Chief Science Officer at the National Lipid Association. He has served as a scientific advisor to Merck, Amgen and Sanofi.   Learning objectives: 1. Identify each individual's risk for cardiovascular disease and counsel them on benefits of therapy. 2. Learn to lower atherogenic lipids by any means necessary and understand the effects of the common lipid lowering drugs 3. Effectively counsel patients on benefits of lipid lowering drugs to promote patient buy in and adherence.   Clinical Pearls 1. Omega 3 fatty acids at 1,000 mg daily or more is useful for prevention of sudden death in post ACS patients. 2. Omega 3 fatty acids at dose of 4,000 mg per day is needed to lower triglycerides. Indicated if TG remain above 500 on first line therapy. 3. Hypertriglyceridemia with level above 500 on optimal statin dose, then consider addition of fibrate and/or omega-3 fatty acids. Uncertain clinical benefit in patient with moderate elevation (200-300) of triglycerides. 4. Statin intolerance can be overcome in most patients using the following methods: a. Same statin at lower dose b. Different statin c. Use of rosuvastatin or atorvastatin 3 times weekly 5. Statins are safe to take for at least 20 years and probably longer (this data is still being collected, but will be available in the future) 6. Withdrawal of statins at the end of life is not harmful and may be beneficial.   Links from the Show:   Studies that used fibrates for preventions of CV events: Helsinki Heart Study for primary prevention NEJM 1987 VA HIT Study for secondary prevention NEJM 1999   Withdrawal of statins at the end of life http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618294/   Expert Consensus on use of Non-Statin Drugs http://www.acc.org/latest-in-cardiology/ten-points-to-remember/2016/03/30/11/58/2016-acc-expert-consensus-decision-pathway-on-the-role-of-nonstatin   National Lipid Association recommendations for patient-centered management of dyslipidemia https://www.lipid.org/sites/default/files/Recommendations-Part-1.pdf   Recommended websites National Lipid Association The Heart.org (Medscape) Journal of Clinical Lipidology

Commentary by Dr. Valentin Fuster

Fantasy Football- Expert Consensus RankingWith: Shane McMurdo & Ricky SinnigEverybody's Fantasy Football drafts are coming and this week we talk about expert consensus rankings in fantasy football. Tune in with Shane (@Thee_Shane_MCM) , Walter "Wojo" (@Brojodeathpunch) and Ricky Sinnig as they breakdown how to utilize "Expert Consensus Rankings" (ECR) and what effect they have on some players ADP and the current players that seem to be getting a boost or a drop from said ECR.#FantasyFootball #NFL #FantasyFootballAdvice #FantasyExpertConsensesRankings #NFL #NFLFantasyPlayers #ECR #FantasyECR #FantasyFootballMemes #FantasyFootballRanksFollow Shane at: @Thee_Shane_MCMFollow Walter at: @BrojoDeathpunchFollow the podcast on twitter: @draftviceon Instagram: @draftvice_footballhttps://www.facebook.com/Draftvice/The Draftvice crew breaks down some players being bumped up by some of the fantasy apps' "Expert Consensus Rankings". See who Ricky, Walter and Shane think are getting helped or hurt from the ECR. Does the local Denver Broncos fan think Courtland Sutton is going too late? Too High? Branden Cooks? What about the Rookie runningbacks? Lean how to manipulate ECR in this episode of DRAFTVICE!Philip Rivers/Tom Brady/Matt Ryan/Kirk Cousins/Cam Newton (temp rank-Injury issue)/Jared Goff/Carson Wentz/Baker Mayfield/Deshaun Watson/Lamar Jackson/Ben Roethlisberger /Matt Stafford/Kyler Murray/Jimmy Garoppolo/Andy Dalton/Dak Prescott/Sam Darnold/ Josh Allen/Marcus Mariota/ Aaron Rodgers/Patrick Mahomes/Andrew Luck/Russell Wilson/ Drew Brees/Mitch Trubisky/Derek Carr/Nick Foles/Jameis Winston/Josh Rosen/Joe Flacco/Eli Manning/Dwayne Haskins/ Case Keenum